Atomic-AI

Atomic-AIAtomic-AI
Atomic-AI

Atomic-AI

AI platform for drug discovery and development, accelerating research with advanced computational tools.

Website
DR 332022Active30San Francisco, United States
Rate
Advertise here

About

Atomic AI is developing RNA-centric medicines using a platform that fuses machine learning and structural biology. Their core product, the ATOM-1 foundation model, enables precise predictions of RNA 3D structure to unlock new therapeutic targets. They serve the field of drug discovery, focusing on RNA-targeted small molecules and RNA-based therapeutics.
HEADCOUNT
30
DOMAIN RATING
33
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Atomic-AI do?

Atomic AI is developing RNA-centric medicines using a platform that fuses machine learning and structural biology. Their core product, the ATOM-1 foundation model, enables precise predictions of RNA 3D structure to unlock new therapeutic targets. They serve the field of drug discovery, focusing on RNA-targeted small molecules and RNA-based therapeutics.

How much funding has Atomic-AI raised?

Atomic-AI has raised a total of $6.2B in funding. The most recent round on record is Series A.

Where is Atomic-AI headquartered?

Atomic-AI is headquartered in San Francisco, United States.

When was Atomic-AI founded?

Atomic-AI was founded in 2022.

What industry does Atomic-AI operate in?

Atomic-AI operates in Biotech, Drug Discovery, AI-Driven Protein Design, Foundation Model, Generative AI, Machine Learning.

How many employees does Atomic-AI have?

Atomic-AI has approximately 30 people on record.

What is Atomic-AI's revenue?

StartupHub estimates Atomic-AI's annual revenue at $3.4M (range $1.8M to $9.4M, 63% confidence), based on comparable companies in the sector.

What is Atomic-AI's valuation?

StartupHub estimates Atomic-AI's effective valuation at $24.2B (range $15.6B to $37.5B, 20% confidence), based on comparable companies in the sector.